MEJHF yields 3.05% · JNJ yields 2.13%● Live data
📍 MEJHF pulled ahead of the other in Year 1
Combined, MEJHF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MEJHF + JNJ for your $10,000?
Meiji Holdings Co., Ltd., through its subsidiaries, manufactures and sells dairy products, confectioneries, nutritional products, and pharmaceuticals in Japan and internationally. The company operates through two segments, Food and Pharmaceutical. It provides yogurt, cheese, drinking milk, beverages, butter and margarine, cream, ice cream, ready meals, chocolates, gummy products, chewing gums, sports nutrition products, infant formula, liquid diet, beauty supplements, OTC medicines, feed stuffs, corn sweeteners, and sugar, as well as transportation and distribution services. The company also offers drugs for infectious diseases and central nervous system disorders, as well as generic drugs; agricultural and livestock chemicals; human and animal vaccines, and blood plasma products; and veterinary drugs for livestock and fisheries comprising antimicrobial injection, disinfectants, oral administration, insecticides, anthelmintic, antipyretic, analgesic, anti-inflammatory, hemostatic, and breeding agents. In addition, it provides insecticides, metabolites, feed additives, and mixed feed; and companion animals, including anesthetics and painkillers, anti-parasitic and gastrointestinal drugs, anti-bacterial agents, antiplasmin agents, vitamin E preparations, and dietary supplements. Meiji Holdings Co., Ltd. was founded in 1916 and is headquartered in Tokyo, Japan.
Full MEJHF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.